International Stem Cell Corporation (ISCO)
| Market Cap | 1.13M -7.2% |
| Revenue (ttm) | 9.51M +3.4% |
| Net Income | -582.00K |
| EPS | -0.07 |
| Shares Out | 8.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,196 |
| Open | 0.16245 |
| Previous Close | 0.1790 |
| Day's Range | 0.1410 - 0.1799 |
| 52-Week Range | 0.1170 - 0.5400 |
| Beta | -0.04 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About International Stem Cell
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson’s disease, as well as for treating stroke, traumatic brain injury, and Alzheimer’s disease. The company offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, Pr... [Read more]
Financial Performance
In 2025, International Stem Cell's revenue was $9.10 million, an increase of 0.17% compared to the previous year's $9.09 million. Losses were -$418,000, 100.0% more than in 2024.
Financial StatementsNews
International Stem Cell reports FY24 EPS (3c) vs. (2c) last year
Reports revenue $9.1M vs. $7.8M last year. “2024 has been a successful year for International Stem Cell (ISCO) Corporation, marked by both strong financial performance and continued progress in our…
International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End Results
SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotech...
Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.
TOKYO--(BUSINESS WIRE)--Kasturba medical college, XVIII Fujio cup quiz winners along with finalists become FCQ elites, an eligibility to nominate Edogawa NICHE Prize awardees.
International Stem Cell Corporation Announces Strong Financial Results for the Quarter Ended March 31, 2022
SAN DIEGO, CA / ACCESSWIRE / May 17, 2022 / International Stem Cell Corporation (OTC PINK:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnolo...